Top 10 States for Early-Career Physicians - Scorecard - MDSpire

Top 10 States for Early-Career Physicians

These 10 states reported physician residency completion totals, physician retention rates, or residency Match fill rates identified in graduate medical education data.

  • By

  • Conexiant News Staff

  • June 1, 2026

  • 3 min

Share

Clinical Scorecard: Top 10 States for Early-Career Physicians

At a Glance

CategoryDetail
ConditionPhysician Residency Training and Retention
Key MechanismsResidency training volume, physician retention rates, and Match activity
Target PopulationEarly-career physicians in the United States
Care SettingResidency training programs

Key Highlights

  • California has the highest residency training volume and retention rate at 75.7%.
  • Illinois achieved a 99.7% fill rate in the 2025 Main Residency Match.
  • Massachusetts and Wisconsin both reported fill rates of 99.8% in their residency programs.
  • Michigan had a 99.9% fill rate, with 45 more positions offered than in 2024.
  • Ohio and New Jersey offered more positions in 2025 compared to the previous year.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not applicable

          Not applicable

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Top 10 States for Early-Career Physicians

            • by Conexiant News Staff

            • June 1, 2026

            Related Content

            Head-to-Head Trial in Relapsing MS

            The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

            FDA Approves First Oral PCSK9 Inhibitor

            Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

            FDA Expands Test for Gastric and Esophageal Cancers

            According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.